TrialInvestigational new drugs2018

Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients.

Won Young Tak et al.PubMed ↗Publisher ↗

No numbers read from the abstract.